Background: Few data are available on the clinical features of patients who develop breakthrough bacteraemia, understood as positive blood cultures despite appropriate antibiotic therapy.
Objectives: To determine the clinical significance and outcome of a large series of breakthrough bacteraemia.
Design: Retrospective analysis of a prospectively collected database.
Setting: Two university-affiliated hospitals in Catalonia, Spain.
Subjects: A total of 392 individuals who suffered an episode of breakthrough bacteraemia recorded between 1997 and 2002.
Interventions: Demographic characteristics, underlying diseases, origin of infection, sources of infection, microorganisms isolated, McCabe and Jackson prognostic criteria, and mortality were analysed.
Results: Breakthrough bacteraemia was detected in 392 of 6324 (6.1%) episodes of bacteraemia. Eighty per cent of episodes were nosocomial. The most frequent source of infection in breakthrough bacteraemia was endovascular (70%). Coagulase-negative staphylococci, Staphylococcus aureus, and Pseudomonas aeruginosa were the most significant microorganisms involved. Nosocomial acquisition together with selected sources (central venous catheter, endocarditis and other endovascular foci), underlying conditions (neutropenia, polytraumatism, allogenic bone marrow and kidney transplantation), and particular microbial aetiologies (S. aureus, P. aeruginosa and polymicrobial) were independently associated with increased risk for developing breakthrough bacteraemia. Crude mortality rate was greater in patients with breakthrough bacteraemia (16% vs. 12.3%; P<0.05), and this condition was an independent predictor of death (OR 1.4, 95% CI, 1-1.9; P=0.04).
Conclusions: In view of a case of breakthrough bacteraemia it is mandatory to search for an endovascular focus. Empiric treatment should be directed to cover S. aureus, coagulase-negative staphylococci and nonfermentative Gram-negative bacilli. Breakthrough bacteraemia is an independent predictor of death.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2796.2005.01513.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality.
Microbiol Spectr
January 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Patients with hematological diseases are at high risk for (SM) bacteremia. This study retrospectively analyzed the clinical characteristics and risk factors for 28-day mortality among 140 adult hematological patients diagnosed with SM bacteremia from January 2012 to July 2023. he overall 28-day mortality was 31.
View Article and Find Full Text PDFMulticenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients.
Open Forum Infect Dis
July 2024
Division of Infectious Diseases, Department of Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA.
Background: Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes.
Methods: A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned.
Comparison of fungemia caused by Candida and non-Candida rare yeasts: a retrospective study from a tertiary care hospital.
Med Mycol
May 2024
Department of Public Health, Medical Faculty, Eskisehir Osmangazi University, 26040, Eskisehir, Turkey.
Article Synopsis
- Non-Candida rare yeasts (NCY) are being reported more as causes of serious infections called fungemia, even though Candida is more common.
- This study looked at patients with NCY fungemia compared to those with Candida fungemia to understand their differences and how they respond to antifungal treatments.
- It found that people with certain health problems, like blood cancers and weakened immune systems, are more likely to get infections from NCY, which is a growing concern, especially in hospitals.
Risk factors for resistant gram-positive bacteremia in febrile neutropenic patients with cancer.
J Infect Chemother
October 2024
Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:
Background: Gram-positive bacteria are frequently resistant to empirical beta-lactams in febrile neutropenic patients with cancer. As microbiology and antibiotic susceptibility changes, we reevaluated the risk factors for resistant Gram-positive bacteremia in febrile neutropenic patients with cancer.
Methods: Episodes of bacteremic febrile neutropenia in Seoul National University Hospital from July 2019 to June 2022 were reviewed.
ventricular assist device infections: findings from ineffective phage therapies in five cases.
Antimicrob Agents Chemother
April 2024
Institute of Biomedical and Oral Research (IBOR), Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Left ventricular assist devices (LVAD) are increasingly used for management of heart failure; infection remains a frequent complication. Phage therapy has been successful in a variety of antibiotic refractory infections and is of interest in treating LVAD infections. We performed a retrospective review of four patients that underwent five separate courses of intravenous (IV) phage therapy with concomitant antibiotic for treatment of endovascular LVAD infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!